HDAC9 and acute myeloid leukemia: In the present study, we investigated the efficacy of entinostat, a class I specific HDAC inhibitor with antileukemic and differentiation-inducing activity in AML [18], to sensitize AML blasts to ATRA, to a degree shown with the DNA hypomethylating agent decitabine.